EUVIMEDOpdag EUVIMED
Crossref

Comprehensive clinical outcomes of drug‐coated balloon treatment for coronary artery disease. Insights from a single‐center experience

Atsushi Funatsu iD, Tatsushi Sato, Jumpei Koike, Masahiro Mizobuchi, Tomoko Kobayashi, Shigeru Nakamura

Catheterization and Cardiovascular Interventions · 2024

DOI: 10.1002/ccd.30945 ↗

At a glance

Journal article in Catheterization and Cardiovascular Interventions, 2024. Written by Atsushi Funatsu and 5 co-authors. Institution: Cardiovascular Center, Kyoto Katsura Hospital, Kyoto, Japan. Major MEDLINE topics: Coronary Artery Disease, Percutaneous Coronary Intervention, Coronary Restenosis. Cited 7 times so far (Crossref); 32 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Some clinical trials have verified the efficacy and safety of paclitaxel drug‐coated balloon (DCB) for small vessel coronary artery disease. However, nonsmall vessel and calcified lesions received less attention.

Aims

This study aimed to investigate the efficacy of DCB treatment for various types of coronary artery lesions, including not only small vessel disease but also nonsmall vessel disease and calcified lesions. In this real‐world clinical practice study, in‐stent restenosis was excluded.

Methods

This study consecutively included 934 patients with 1751 nonstented lesions who received DCB at a cardiovascular center in Kyoto Katsura Hospital in Japan between 2009 and 2012 and 2014 to 2019. This study enrolled and retrospectively analyzed all of the patients. Eligible patients routinely underwent follow‐up angiography at 6–8 months after percutaneous coronary intervention. The primary endpoint includes target lesion revascularization (TLR) during follow‐up. Further, this study calculated the predictor of TLR using multivariate analysis.

Results

This study included the lesions involving 46.4% of type B2/C, 26.9% with severe calcification, and 6.0% with DCB restenosis. Mean DCB diameter and length were 2.75 ± 0.51 mm and 24.2 ± 9.6 mm, respectively. The median follow‐up duration was 18 months. Follow‐up angiography revealed a TLR rate of 9% and a restenosis rate of 9%. This study identified hemodialysis and current smoking as independent TLR predictors.

Conclusion

In routine clinical practice, the effectiveness of DCB was observed consistently across various types of coronary artery disease.

Subjects

MeSH terms (MEDLINE)

Coronary Artery DiseasePercutaneous Coronary InterventionCoronary RestenosisHumansRetrospective StudiesTreatment OutcomePaclitaxelConstriction, PathologicCoated Materials, BiocompatibleCoronary Angiography

Author keywords

coronary artery diseasedrug-coated balloontarget lesion revascularization

Substances

PaclitaxelCoated Materials, Biocompatible

Authors and institutions

  • Cardiovascular Center, Kyoto Katsura Hospital, Kyoto, Japan.

ORCID profiles: Atsushi Funatsu

Cite

APA

Funatsu, A., Sato, T., Koike, J., Mizobuchi, M., Kobayashi, T., & Nakamura, S. (2024). Comprehensive clinical outcomes of drug‐coated balloon treatment for coronary artery disease. Insights from a single‐center experience. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.30945

Vancouver

Funatsu A, Sato T, Koike J, Mizobuchi M, Kobayashi T, Nakamura S. Comprehensive clinical outcomes of drug‐coated balloon treatment for coronary artery disease. Insights from a single‐center experience. Catheterization and Cardiovascular Interventions. 2024. doi:10.1002/ccd.30945

BibTeX
@article{Funatsu2024,
  author = {Funatsu, Atsushi and Sato, Tatsushi and Koike, Jumpei and Mizobuchi, Masahiro and Kobayashi, Tomoko and Nakamura, Shigeru},
  title = {Comprehensive clinical outcomes of drug‐coated balloon treatment for coronary artery disease. Insights from a single‐center experience},
  journal = {Catheterization and Cardiovascular Interventions},
  year = {2024},
  doi = {10.1002/ccd.30945}
}
Start for free →